Drug Trial Radar · NCT04213105
Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Dec 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
144
Planned (sponsor's estimate)
Start
Oct 31, 2019
Primary completion
Oct 31, 2020
Study completion Oct 31, 2020
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 30, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A randomized, double-blind and parallel group study to compare the pharmacokinetic, safety and pharmacodynamic of QL1206 and Prolia® in healthy adults
Conditions
- Healthy People
Interventions
QL1206Drug
subcutaneous injection of 60 mg (1ml) only once,on the first day.
Prolia®Drug
subcutaneous injection of 60 mg (1ml)only once,on the first day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the plasma concentration-time curve (AUC0-t )Time frame: 134 day
- maximum plasma concentration(Cmax)Time frame: 134 day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Jilin University
Changchun, Jilin, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.